December 7, 2024
The two melanoma patients mentioned above [9] and the patient we describe here shared the HLA-DQB1*03:01 allele, however this HLA- allele is very frequent, being expressed by more than 30% of Caucasian
4 min read

The two melanoma patients mentioned above [9] and the patient we describe here shared the HLA-DQB1*03:01 allele, however this HLA- allele is very frequent, being expressed by more than 30% of Caucasian

cmerp January 18, 2022
The two melanoma patients mentioned above [9] and the patient we describe here shared the HLA-DQB1*03:01 allele,...
Read More
3)
3 min read

3)

cmerp January 12, 2022
3). whose delivery was reduced by anti-CLU antibody less than apolipoprotein-enhanced and regular conditions. Coimmunoprecipitation revealed a...
Read More
Improving Malignancy Chemotherapy Performance by Blocking LPA-Mediated Inflammatory Signaling Given the considerable overlap between fibrotic and carcinoma pathways [136], LPA signaling inhibitors are expected to serve as useful adjuncts in cancer therapy, largely by mitigating the loss of efficacy for chemotherapy and radiotherapy via blockage of the pro-survival benefits of tumor-promoting inflammation
3 min read

Improving Malignancy Chemotherapy Performance by Blocking LPA-Mediated Inflammatory Signaling Given the considerable overlap between fibrotic and carcinoma pathways [136], LPA signaling inhibitors are expected to serve as useful adjuncts in cancer therapy, largely by mitigating the loss of efficacy for chemotherapy and radiotherapy via blockage of the pro-survival benefits of tumor-promoting inflammation

cmerp January 9, 2022
Improving Malignancy Chemotherapy Performance by Blocking LPA-Mediated Inflammatory Signaling Given the considerable overlap between fibrotic and carcinoma...
Read More
Similarly, compound 6 protected against the LRRK2:G2019SCinduced decreases in MMP in a dose dependent manner where 10 M compound 6 returned MMP dissipation to untreated levels (Figure 6B)
3 min read

Similarly, compound 6 protected against the LRRK2:G2019SCinduced decreases in MMP in a dose dependent manner where 10 M compound 6 returned MMP dissipation to untreated levels (Figure 6B)

cmerp January 7, 2022
Similarly, compound 6 protected against the LRRK2:G2019SCinduced decreases in MMP in a dose dependent manner where 10...
Read More

You may have missed

Therefore, corticosteroid resistance or refractory ADs was considered
3 min read

Therefore, corticosteroid resistance or refractory ADs was considered

November 26, 2024
patients
1 min read

patients

November 25, 2024
With all the traditionally accepted cut-off point of the four-fold or greater upsurge in titers, 82% (37/45) were classified simply because having seroconverted simply by HI, that was slightly significantly less than the 89% (39/44) with the VM assay
3 min read

With all the traditionally accepted cut-off point of the four-fold or greater upsurge in titers, 82% (37/45) were classified simply because having seroconverted simply by HI, that was slightly significantly less than the 89% (39/44) with the VM assay

November 23, 2024
Recognition of bound major antibodies was performed with AP substrate after incubation with goat anti-rabbit antibodies
3 min read

Recognition of bound major antibodies was performed with AP substrate after incubation with goat anti-rabbit antibodies

November 22, 2024